Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Mestre Borras

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Cell Reports Methods|June 11, 2025
Engineering high-efficiency matriptase substrates using E. coli display for applications in prodrug activationAnna Mestre Borras, Hanna Mehari, Stefan Ståhl, et al.
Biochemical and Biophysical Research Communications|March 21, 2025
Affibody-based HER2 prodrug shows conditional cytotoxic effect on HER2-positive cancer cellsCornelia Westerberg, Anna Mestre Borras, Stefan Ståhl, et al.
Protein Engineering, Design & Selection : PEDS|April 16, 2026
Engineering affibody domains as anti-idiotypic masks for nivolumab-based prodrugsAnna Mestre Borras, Hanna Mehari, Stefan Ståhl, et al.
New Biotechnology|December 16, 2022
Generation of an anti-idiotypic affibody-based masking domain for conditional activation of EGFR-targetingAnna Mestre Borras, Charles Dahlsson Leitao, Stefan Ståhl, et al.
Biotechnology Journal|July 14, 2023
Engineering of TEV protease variants with redesigned substrate specificitySebastian W Meister, Luke Parks, Leonie Kolmar, et al.
Biomedicines|June 24, 2022
Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody MoleculesSara S Rinne, Wen Yin, Anna Mestre Borras, et al.
Frontiers in Microbiology|August 10, 2019
Enhancing Recombinant Protein Yields in the <i>E. coli</i> Periplasm by Combining Signal Peptide and Production Rate ScreeningAlexandros Karyolaimos, Henry Ampah-Korsah, Tamara Hillenaar, et al.
Frontiers in Bioengineering and Biotechnology|February 18, 2020
<i>Escherichia coli</i> Can Adapt Its Protein Translocation Machinery for Enhanced Periplasmic Recombinant Protein ProductionAlexandros Karyolaimos, Katarzyna Magdalena Dolata, Minia Antelo-Varela, et al.
Biochemical and Biophysical Research Communications|March 18, 2023
Display of a naïve affibody library on staphylococci for selection of binders by means of flow cytometry sortingCharles Dahlsson Leitao, Anna Mestre Borras, Andreas Jonsson, et al.
ACS Pharmacology & Translational Science|November 20, 2025
Affibody-Derived Drug Conjugates Targeting The Epidermal Growth Factor Receptor Are Potent And Specific Cytotoxic AgentsSara S Rinne, Wen Yin, Ruonan Li, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Cell Reports Methods|June 11, 2025
Engineering high-efficiency matriptase substrates using E. coli display for applications in prodrug activationAnna Mestre Borras, Hanna Mehari, Stefan Ståhl, et al.
Biochemical and Biophysical Research Communications|March 21, 2025
Affibody-based HER2 prodrug shows conditional cytotoxic effect on HER2-positive cancer cellsCornelia Westerberg, Anna Mestre Borras, Stefan Ståhl, et al.
Protein Engineering, Design & Selection : PEDS|April 16, 2026
Engineering affibody domains as anti-idiotypic masks for nivolumab-based prodrugsAnna Mestre Borras, Hanna Mehari, Stefan Ståhl, et al.
New Biotechnology|December 16, 2022
Generation of an anti-idiotypic affibody-based masking domain for conditional activation of EGFR-targetingAnna Mestre Borras, Charles Dahlsson Leitao, Stefan Ståhl, et al.
Biotechnology Journal|July 14, 2023
Engineering of TEV protease variants with redesigned substrate specificitySebastian W Meister, Luke Parks, Leonie Kolmar, et al.
Biomedicines|June 24, 2022
Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody MoleculesSara S Rinne, Wen Yin, Anna Mestre Borras, et al.
Frontiers in Microbiology|August 10, 2019
Enhancing Recombinant Protein Yields in the <i>E. coli</i> Periplasm by Combining Signal Peptide and Production Rate ScreeningAlexandros Karyolaimos, Henry Ampah-Korsah, Tamara Hillenaar, et al.
Frontiers in Bioengineering and Biotechnology|February 18, 2020
<i>Escherichia coli</i> Can Adapt Its Protein Translocation Machinery for Enhanced Periplasmic Recombinant Protein ProductionAlexandros Karyolaimos, Katarzyna Magdalena Dolata, Minia Antelo-Varela, et al.
Biochemical and Biophysical Research Communications|March 18, 2023
Display of a naïve affibody library on staphylococci for selection of binders by means of flow cytometry sortingCharles Dahlsson Leitao, Anna Mestre Borras, Andreas Jonsson, et al.
ACS Pharmacology & Translational Science|November 20, 2025
Affibody-Derived Drug Conjugates Targeting The Epidermal Growth Factor Receptor Are Potent And Specific Cytotoxic AgentsSara S Rinne, Wen Yin, Ruonan Li, et al.
Pageof 2